Last Updated on Wednesday, December 04, 2013
Tuesday, December 03, 2013
Yesterday, Chemical & Engineering News featured an article about the early detection of preeclampsia. Preeclampsia Foundation Executive Director Eleni Tsigas was interviewed, and the leading tests to identify and predict the life-threatening pregnancy complication were reviewed. The Preeclampsia Foundation eagerly observes and applauds the advances being made in molecular tests (biomarkers) to confirm diagnosis of preeclampsia and to predict early in pregnancy a woman’s likelihood of developing preeclampsia.
“Biomarkers are leading tests to identify the life-threatening pregnancy complication before it becomes deadly,” reports Celia Henry Arnaud, author of “Early Detection of Preeclampsia” in the December 2, 2013 issue of Chemical & Engineering News.
Noted among the innovators working in this area were:
- Alere, a multinational corporation of several diagnostic and health management companies, working on a diagnosis confirmation test based on placental growth factor (PlGF). (See GUEST BLOG in this newsletter, below.)
- Screening for Pregnancy Endpoints (SCOPE) Consortium, which has established a biobank of samples from approximately 6,000 pregnant women in the U.K., Australia, New Zealand, and Ireland. The consortium has focused on healthy, low-risk women in their first pregnancy. Samples from this study are being used to help develop predictive tests.
- Thermo Fisher Scientific and PerkinElmer, both of which use biomarkers to calculate a risk score that the mother will develop preeclampsia before 34 weeks. These screening tests are meant to be used at the end of the first trimester, approximately between weeks 10 and 14.
- Pronota, a company in Ghent, Belgium, which is working on a predictive test, using four biomarkers, that will be administered halfway through a pregnancy, at week 20.
- Carmenta Bioscience, based in Palo Alto, California, which is also working on a predictive test and a diagnosis confirmation test.
- Metabolomic Diagnostics, a company based in Cork, Ireland, which has used samples from the SCOPE study to identify metabolites for development of a predictive test that can be used early in pregnancy.